Analysis of the Economic-Financial Efficiency of Gout Treatment in Elderly Patients with Comorbidities in the Republic of Moldova

被引:0
|
作者
Rotaru, Larisa [1 ,2 ]
Groppa, Liliana [1 ,2 ]
Russu, Eugeniu [1 ]
Cazac, Victor [1 ]
Agachi, Svetlana [1 ]
Codreanu, Catalin [3 ]
Spinei, Larisa [4 ]
Arnaut, Oleg [5 ]
Sarbu, Oxana [1 ]
Cornea, Cornelia [1 ]
机构
[1] Univ Stat Med & Farmacie Nicolae Testemitanu, Dept Internal Med Rheumatol & Nephrol, Nicolae Testemitanu Str 29, Kishinev, Moldova
[2] Timofei Mosneaga Republican Clin Hosp, Rheumatol Lab, Kishinev, Moldova
[3] Carol Davila Univ Med & Pharm, Dept Internal Med Cardiol 5, Fac Med, Fac Dent,Gastroenterol,Hepatol,Rheumatol,Geriatr,F, Bucharest, Romania
[4] Univ Stat Med & Farmacie Nicolae Testemitanu, Dept Social Med & Management Nicolae Testemitanu, Kishinev, Moldova
[5] Univ Stat Med & Farmacie Nicolae Testemitanu, Informat Lab, Kishinev, Moldova
来源
MEDITERRANEAN JOURNAL OF RHEUMATOLOGY | 2023年 / 34卷 / 03期
关键词
gout; statistics; comorbidity; BURDEN; BONE;
D O I
10.31138/mjr.20230725.ao
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The costs of treating an elderly patient with gout are largely related to the treatment of concomitant pathological conditions and complications. Determining the costs of treating the disease is made by clinical and economic analysis, the task of which is to calculate the "cost of the illness". Material and methods: A descriptive, selective study of 237 patients with gout. In order to study the clinical characteristics of gout in the elderly, all those included in the study was divided according to age at the time of examination: group I made up of patients with gout up to and including 59 years n=91, average age 48.1 +/- 7.4 years (from 30 years to 59 years), group II - over the age of 60 years inclusive n=146, average age 69.2 +/- 6.0 years, (60-86 years, p<0.01). Results: For calculations, the hospitalisation rate during the year was used, which had significant differences in groups: in group I it was 0.7; in group II - 1.2 (p=0,001). The costs of clinical management of gout and each of the diseases that accompany it for 1 calendar year have been determined. Conclusions: The direct costs for the treatment of patients with gout, calculated taking into account National Clinical Protocol and comorbid pathology, increase significantly with the age of the patients: the average cost per year of the treatment of gout in patients of mature age was 1337 Euro without and 7320 Euro taking into account the concomitant pathology, and in the elderly 2067 Euro and, respectively, 15230 Euro.
引用
收藏
页码:327 / 331
页数:6
相关论文
共 30 条
  • [1] Comorbidities in elderly patients with asthma: Association with control of the disease and concomitant treatment
    Wardzynska, Aleksandra
    Kubsik, Beata
    Kowalski, Marek Leszek
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2015, 15 (07) : 902 - 909
  • [2] Psychiatric Comorbidities among Iranian Elderly Patients on Methadone Maintenance Treatment
    Mortazavi, Seyede Salehe
    Shati, Mohsen
    Malakouti, Seyed Kazem
    Mohammad, Kazem
    ARCHIVES OF IRANIAN MEDICINE, 2015, 18 (11) : 740 - 746
  • [3] Relationship between comorbidities and treatment decision-making in elderly hip fracture patients
    Wei, Jinxing
    Zeng, Li
    Li, Shitong
    Luo, Fang
    Xiang, Zhou
    Ding, Qunfang
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 31 (12) : 1735 - 1741
  • [4] Relationship between comorbidities and treatment decision-making in elderly hip fracture patients
    Jinxing Wei
    Li Zeng
    Shitong Li
    Fang Luo
    Zhou Xiang
    Qunfang Ding
    Aging Clinical and Experimental Research, 2019, 31 : 1735 - 1741
  • [5] The Predictive Values of the Functional Status, Comorbidities, and the Types of Treatment on the Treatment Outcomes in Elderly Patients Following the Hip Fracture
    Dozic, H.
    Biscevic, M.
    Muharemovic, T.
    Zujo, S.
    Kukuljac, A.
    Skopljak, E.
    ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA, 2022, 89 (03) : 199 - 203
  • [6] Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients
    Yan, C. -Q.
    Liang, C.
    Lan, Z. -R.
    Su, C.
    Xiong, S. -Y.
    Yang, Y. -X.
    Chen, J. -M.
    Tang, S. -L.
    Huang, J. -S.
    Zhang, Z. -H
    Luo, M. -J.
    Xiao, Z. -H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (24) : 11988 - 12003
  • [7] Analysis of the Economic Burden of Chronic Kidney Disease With Comorbidities Among Patients in Xuzhou, China
    Jie, Wan
    Yao, Minghong
    Wang, Mingqi
    Wang, Yuning
    Jia, Yulong
    Liu, Yanmei
    Zou, Kang
    Sun, Xin
    INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2024, 69
  • [8] Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population
    Shah, Chintal H.
    Onukwugha, Eberechukwu
    Zafari, Zafar
    Villalonga-Olives, Ester
    Park, Jeong-eun
    Slejko, Julia F.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 683 - 690
  • [9] The influence of pulmonary comorbidities on treatment choice and short-term surgical outcomes among elderly patients with colorectal cancer
    Nishikawa, Takeshi
    Kawai, Kazushige
    Emoto, Shigenobu
    Murono, Koji
    Hiyoshi, Masaya
    Kaneko, Manabu
    Sonoda, Hirofumi
    Sasaki, Kazuhito
    Shuno, Yasutaka
    Tanaka, Toshiaki
    Hata, Keisuke
    Nozawa, Hiroaki
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2019, 34 (08) : 1497 - 1501
  • [10] The influence of pulmonary comorbidities on treatment choice and short-term surgical outcomes among elderly patients with colorectal cancer
    Takeshi Nishikawa
    Kazushige Kawai
    Shigenobu Emoto
    Koji Murono
    Masaya Hiyoshi
    Manabu Kaneko
    Hirofumi Sonoda
    Kazuhito Sasaki
    Yasutaka Shuno
    Toshiaki Tanaka
    Keisuke Hata
    Hiroaki Nozawa
    International Journal of Colorectal Disease, 2019, 34 : 1497 - 1501